FOGC MAJOR UPDATE I GOT BACK FROM COMPANY BY EMAIL BELOW...
Andrew,
I am the primary business consultant for Manzo Pharmaceuticals, and I think I can answer your question.
First, even if I knew, I couldn’t tell you what is in the next PR’s, but the CEO has to keep that very confidential. I can tell you that, yes, you are correct, the outstanding shares is very high because of the fact that it was already that was pre-merge, and likely that is the cause for the flat share price. There are lots of shares owned by previous investors and they are probably selling to recoup some of the lost value they experienced. It is my belief that once they are out of the way, the stock should react favorably, but this is the Pinksheets so you never can accurately predict what will happen.
I can tell you for sure that one of the CEO’s goals is definitely reducing the outstanding shares to increase shareholder value, so although I couldn’t confirm that anything specific is planned, I would bet that buybacks, cancellations, and other methods are in the works moving forward, except of course a reverse split, which the CEO has vowed not to do. The company will not benefit from holding onto information for very long unless it is necessary, so I imagine that Mr. Manzo will announce any buybacks, or cancellations as soon as it is appropriate to do so.
I would also like to add that it is not unusual for a pharmaceutical company like Manzo Pharmaceuticals to have a 3-4 billion share float. I just think in this case the market has not had a chance to respond and the company has not had a chance to put out enough information to warrant it yet. of course that is just my opinion.
